Drug, across the briefings

Tazemetostat across 3 cancers

Tazemetostat appears in 3 of the briefings; its FDA label names 2 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Follicular lymphoma	label names disease	approved on EZH2	20	7
Soft tissue sarcoma	label names disease		—	—
Diffuse large B-cell lymphoma		approved on EZH2	12	4

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.